🔗 Share this article

While the United States undertakes sweeping changes to its vaccination guidelines, an unexpected name has surfaced unexpectedly: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who initially gained attention by expressing skepticism about COVID-19 shots throughout the global health crisis and has concentrated on alleged fatalities following COVID-19 vaccination in her short time at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Program

Agency leaders were set to announce major revisions to the childhood vaccine schedule earlier this month, bringing the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US at odds with much of the global community with no evidence for benefit. The planned update has been delayed until the new year.

In place of Vinay Prasad, Høeg is listed to present at the meeting. She was newly appointed interim head of the FDA’s CDER, the fifth individual to lead the office this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the pharmaceutical and vaccine centers as Høeg and Prasad consolidate power at the agency – and it points to a greater focus upon rolling back long-standing vaccines at the FDA.

Høeg has frequently advocated for ending specific pediatric immunization guidelines in the US to become more similar to the Danish model, a country with comprehensive healthcare and a number of inhabitants about the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccines – typically the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Questions Over Expertise

Høeg has no obvious background in medication creation, oversight or leadership, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for overseeing the CDER, remarked a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She has no expertise in running a sizeable institution. She is not an expert in pharmaceutical oversight.”

Previous directors of the center would “grasp legal statutes and the science of drug development”, said Janet Woodcock. “Frankly, she has not acquired the sort of resume that previous people who headed the center have had.”

This division has an enormous portfolio at the agency, Woodcock pointed out.

“Everybody just zeroes in on the innovative therapies, but the generic program authorizes a multitude of generic medications. There’s a biosimilars program, non-prescription drug unit and other areas, and each of these must be supervised,” Woodcock said. “The area you overlook, that’s the thing that I always told people is going to bite you.”

There is also, a major management aspect to the position, which oversees over 5,000 employees. “It’s a massive management job, if you execute it properly,” Woodcock added.

Official Statement and Controversial Policies

When asked about questions about Dr. Høeg's fitness for the role and whether this selection indicates more teamwork among regulatory chiefs on vaccines, a spokesperson stated that the “concerns are based on flawed premises”.

“This background aligns with the functions of her position,” the representative said, pointing to the months Dr. Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg inherits the agency head's controversial priority voucher program, a contentious expedited drug-approval program that reportedly worried her predecessors. “How are these medications being chosen for this expedited pathway? Who takes the decisions?” Howard asked. “There is a lot of secrecy going on at the regulatory body right now.”

In general, he remarked, “the Food and Drug Administration seems to be moving towards less stringent rules of all drugs, with the exception of shots.”

Established Track Record on Immunizations

With vaccines, Dr. Høeg has a more established, if troubling, track record, some experts said. She released a analysis using non-validated public submissions to estimate the incidence of heart inflammation after COVID-19 vaccination. She advised the Florida top health official Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccines are riskier than they are.

Among her “wish list” for the incoming federal leadership encompassed altering guidelines for new vaccines and halting “unnecessary” vaccines, she said after the election on a podcast. At the FDA, Høeg has allegedly proposed excluding teenage boys from receiving COVID-19 vaccines.

“She is an all-around dogmatist who begins with her conclusions and works backwards to accommodate the data in a very disingenuous, fraudulent fashion,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined other skeptics, {like|